Mandate

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").

SBB has entered into an agreement to enter into a joint venture company, SBB Infrastructure AB ("SBB Infrastructure"), together with funds managed by the global alternative asset manager Castlelake. In connection with the establishment of the joint venture, SBB Infrastructure has entered into a loan agreement with Castlelake for approximately SEK 5.2 billion. Closing will occur as soon as all closing conditions have been fulfilled, which is expected to be in March 2024.

Vinge's team consisted primarily of Mikael Ståhl, Albert Wållgren, Helena Göransson, Rikard Lindahl, Ulrich Ziche, William Kåge, Kamyar Najmi, Jolinn Uhlin, Nour Makie, Ida Redander and Rebecka Margolin.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025